Page last updated: 2024-08-24

tolafentrine and iloprost

tolafentrine has been researched along with iloprost in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ghofrani, HA; Grimminger, F; Krupnik, E; Rose, F; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Walmrath, D; Weissmann, N	1
Ghofrani, HA; Grimminger, F; Olschewski, H; Rose, F; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Weissmann, N; Wiedemann, R	1
Ermert, L; Ghofrani, HA; Grimminger, F; Kreisselmeier, KP; Pullamsetti, S; Samidurai, A; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N	1

Trials

1 trial(s) available for tolafentrine and iloprost

Article	Year
Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Critical care medicine, 2002, Volume: 30, Issue:11 Topics: Adult; Aerosols; Aged; Area Under Curve; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Naphthyridines; Phosphodiesterase Inhibitors; Statistics, Nonparametric; Vascular Resistance; Vasodilation; Vasodilator Agents	2002

Article

Year

Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension.

Critical care medicine, 2002, Volume: 30, Issue:11

Topics: Adult; Aerosols; Aged; Area Under Curve; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Naphthyridines; Phosphodiesterase Inhibitors; Statistics, Nonparametric; Vascular Resistance; Vasodilation; Vasodilator Agents

2002

Other Studies

2 other study(ies) available for tolafentrine and iloprost

Article	Year
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. American journal of respiratory and critical care medicine, 2001, Nov-01, Volume: 164, Issue:9 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemodynamics; Hypertension, Pulmonary; Iloprost; Naphthyridines; Pentoxifylline; Phosphodiesterase Inhibitors; Rabbits; Vasodilation; Vasodilator Agents	2001
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circulation research, 2004, Apr-30, Volume: 94, Issue:8 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gelatinases; Hemodynamics; Hypertension, Pulmonary; Hypertrophy; Hypertrophy, Right Ventricular; Iloprost; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocrotaline; Muscle, Smooth, Vascular; Naphthyridines; Oxygen; Phosphodiesterase Inhibitors; Pulmonary Artery; Pulmonary Gas Exchange; Pulmonary Heart Disease; Rats; Rats, Sprague-Dawley; Vasodilator Agents; Ventricular Remodeling	2004

Article

Year

Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.

American journal of respiratory and critical care medicine, 2001, Nov-01, Volume: 164, Issue:9

Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemodynamics; Hypertension, Pulmonary; Iloprost; Naphthyridines; Pentoxifylline; Phosphodiesterase Inhibitors; Rabbits; Vasodilation; Vasodilator Agents

2001

Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.

Circulation research, 2004, Apr-30, Volume: 94, Issue:8

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gelatinases; Hemodynamics; Hypertension, Pulmonary; Hypertrophy; Hypertrophy, Right Ventricular; Iloprost; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocrotaline; Muscle, Smooth, Vascular; Naphthyridines; Oxygen; Phosphodiesterase Inhibitors; Pulmonary Artery; Pulmonary Gas Exchange; Pulmonary Heart Disease; Rats; Rats, Sprague-Dawley; Vasodilator Agents; Ventricular Remodeling

2004